Photobiomodulation CME part II: Clinical applications in dermatology.
Level 5 - mechanism / opinion, no new human data
Narrative CME review without systematic review methodology or new primary human data.
PubMed 38307144 · doi:10.1016/j.jaad.2023.10.074
What was done
This continuing medical education (CME) review summarized clinical applications of photobiomodulation (PBM) in dermatology. The review examined the use of red (620–700 nm) and near-infrared (700–1440 nm) light delivered via low-level lasers or light-emitting diodes in both office- and home-based settings.
What was found
The abstract provides no quantitative data, sample sizes, or effect estimates. It qualitatively reports that PBM has been used effectively for adverse effects secondary to cancer therapies, alopecia, ulcers, herpes simplex virus, acne, skin rejuvenation, wounds, and scars, with variable biological effects depending on skin phototype and ethnicity.
Why it matters
PBM is increasingly accessible via in-office and consumer home-use devices, making it important for clinicians to understand current clinical applications, safety profiles, and considerations for skin of color.
Limits
The abstract describes a narrative educational review rather than a systematic synthesis. It reports no specific study counts, quantitative endpoints, or risk of bias assessments, and notes that standardized protocols across skin types remain lacking.
Cited by
- supports Red light exposure from devices or the sun improves wound healing in the skin, reduces acne symptoms, and reduces inflammation.
- partial Long-wavelength light exposure to the skin reduces inflammation, improves skin appearance, and reduces acne in part through improving lymphatic system function.